Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy

Menopause

Volumn 16, Issue 4, 2009, Pages 735-741

  Freedman, Murray ^a   Kaunitz, Andrew M ^b,c   Reape, Kathleen Z ^c   Hait, Howard ^c   Shu, Haibin ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c Duramed Research Inc   (United States)

Author keywords

Dyspareunia; Estrogen therapy; Vaginal atrophy; Vaginal dryness; Vulvovaginal atrophy

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DYSPAREUNIA; ENDOMETRIUM POLYP; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PH MEASUREMENT; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; UPPER RESPIRATORY TRACT INFECTION; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA IRRITATION; VAGINA MYCOSIS; VAGINA SMEAR; VAGINAL BURNING SENSATION; VAGINAL DRYNESS; VENOUS THROMBOEMBOLISM; VULVOVAGINAL DISCOMFORT; VULVOVAGINAL DISEASE; XEROSIS;

AGED; ATROPHY; DOUBLE-BLIND METHOD; DYSPAREUNIA; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES; VAGINAL DISEASES;

EID: 68449085745     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318199e734     Document Type: Article

References (11)

1. Bachmann GA, Vevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090-3096.
2. ACOG Task Force for Hormone Therapy. Summary of balancing risks and benefits. Obstet Gynecol 2004;104:128S-129S.
3. The North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602.
4. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation. January 2003 Clinical/Medical. Available at: http://www.fda.gov/ cder/guidance/5412dft.pdf Accessed October 14, 2008.
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommended Prescribing Information for Health Care Providers and Patient Labeling. November 2005 Clinical/Medical. Available at: http://www.fda.gov/cder/guidance/6932dft.pdf. Accessed October 14, 2008.
6. The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007;14:357-369.
7. Ettinger B, Hait H, Reape KZ, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach. Menopause 2008;15:885-889.
8. Simon JA, Reape KZ, Wininger S, Hait H. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Fertil Steril 2008;90:1132-1138.
9. Simon JA, Bouchard C, Waldbaum A, et al. Low dose of transdermal estradiol gel for treatment of symptomatic postmenopausal women. A randomized controlled trial. Obstet Gynecol 2007;109:588-596.
10. Bachmann G, Lobo RA, Gut R, et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis. Obstet Gynecol 2008;111:67-76.
11. Freedman M, Kaunitz A, Reape KZ, et al. Twice-weekly synthetic conjugated estrogens vaginal cream compared with placebo for vaginal atrophy. Obstet Gynecol 2008;111:26S.